{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=51&state=Georgia",
    "query": {
      "state": "Georgia",
      "city": "Atlanta",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 13084,
    "total_pages": 1309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=52&state=Georgia&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=50&state=Georgia&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:58:41.941Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05633654",
      "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan-hziy (SG)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1514,
      "start_date": "2022-12-12",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 188,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05633654"
    },
    {
      "nct_id": "NCT01140451",
      "title": "Extension Study of Ataluren (PTC124) in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ataluren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2010-08-12",
      "completion_date": "2013-12-02",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01140451"
    },
    {
      "nct_id": "NCT00467402",
      "title": "Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "agomelatine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 644,
      "start_date": "2007-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 78,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467402"
    },
    {
      "nct_id": "NCT03093402",
      "title": "JBT-101 in Systemic Lupus Erythematosus (SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "SLE",
        "Lupus"
      ],
      "interventions": [
        {
          "name": "JBT-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 109,
      "start_date": "2017-12-21",
      "completion_date": "2021-07-28",
      "has_results": true,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 16,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03093402"
    },
    {
      "nct_id": "NCT04197453",
      "title": "The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ASCVD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "40 Years to 99 Years"
      },
      "enrollment_count": 752,
      "start_date": "2019-12-06",
      "completion_date": "2020-12-21",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 143,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197453"
    },
    {
      "nct_id": "NCT00082745",
      "title": "Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Childhood Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 3885,
      "start_date": "2004-03-25",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 134,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 102 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082745"
    },
    {
      "nct_id": "NCT04980872",
      "title": "A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)"
      ],
      "interventions": [
        {
          "name": "Miransertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "2 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-11-02",
      "completion_date": "2030-02-07",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980872"
    },
    {
      "nct_id": "NCT02825251",
      "title": "Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Faster-acting insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 472,
      "start_date": "2016-07-06",
      "completion_date": "2017-07-21",
      "has_results": true,
      "last_update_posted_date": "2019-11-21",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 30,
      "location_summary": "Encino, California • Fresno, California • Roseville, California + 25 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02825251"
    },
    {
      "nct_id": "NCT02542631",
      "title": "Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Bolus Insulin Patch (Calibra Finesse)",
          "type": "DEVICE"
        },
        {
          "name": "Insulin Pen (Novo-Nordisk FlexPen®)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Calibra Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "22 Years to 75 Years"
      },
      "enrollment_count": 278,
      "start_date": "2015-08-01",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02542631"
    },
    {
      "nct_id": "NCT02042183",
      "title": "Lubiprostone in Children With Functional Constipation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Constipation - Functional"
      ],
      "interventions": [
        {
          "name": "Lubiprostone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sucampo Pharma Americas, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 606,
      "start_date": "2013-12-13",
      "completion_date": "2016-07-27",
      "has_results": true,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-11-18T23:58:41.941Z",
      "location_count": 87,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02042183"
    }
  ]
}